Results 251 to 260 of about 5,652,944 (334)

Movement Disorders Associated with 22q11.2 Microdeletion: A Scoping Review

open access: yesMovement Disorders Clinical Practice, EarlyView.
Abstract Background Movement disorders have recently emerged as important neurologic manifestations of the 22q11.2 microdeletion that affects nearly one in every 2000 live births. Objective We aimed to map the existing evidence regarding the spectrum, diagnosis and treatment, and etiopathogenesis of movement disorders associated with 22q11.2 ...
Nikolai Gil D. Reyes   +6 more
wiley   +1 more source

Complementary and Integrative Medicine for the Treatment of Tourette's Syndrome

open access: yesMovement Disorders Clinical Practice, EarlyView.
Abstract Background There is widespread interest in complementary and integrative medicine (CIM) among people with Tourette's syndrome (TS). Objective To perform a systematic review of evidence on the use of CIM to reduce tics and improve tic‐related quality of life.
Tamara Pringsheim   +21 more
wiley   +1 more source

COVID-19, sense of control, and the rise of addictive behaviors: a study in Poland. [PDF]

open access: yesPostep Psychiatr Neurol
Górowska MP   +4 more
europepmc   +1 more source

Innovation in Rural Nonprofits: Which Organizational Capacities Matter Most?

open access: yesNonprofit Management and Leadership, EarlyView.
ABSTRACT This research note draws on theory and empirical research from the broader fields of management, organizational capacity, and innovation to examine how specific organizational capacities relate to innovation in a sample of 107 rural nonprofit organizations in a Southeastern U.S. state.
Kristina Jaskyte   +2 more
wiley   +1 more source

Psychiatric Safety of Tirzepatide in People With Obesity and No Known Major Psychopathology: A Post Hoc Analysis of SURMOUNT

open access: yesObesity, EarlyView.
ABSTRACT Objective This post hoc analysis assessed psychiatric changes with tirzepatide in adults with obesity, without known major psychopathology, from SURMOUNT‐1, SURMOUNT‐2, and SURMOUNT‐3. Methods In participants (N = 4056) treated with tirzepatide (5/10/15 mg or maximum tolerated dose 10/15 mg) versus placebo, depressive symptoms and suicidal ...
Thomas A. Wadden   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy